摘要:
The present invention provides cromakalim prodrugs, compositions, and their use for the modulation of ATP-sensitive potassium (KATP) channels for therapeutic purposes.
摘要:
A compound according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein where the integers Q, R 2, A, R 1 , Z 1 , Z 2 , and Z 3 are as defined in claim 1.
摘要:
The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.
摘要:
The present disclosure is generally directed to compounds of Formula (I) that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.
摘要:
Disclosed are pyruvate kinase M2 activators, which are bis sulfonamide piperazinyl and piperidinyl compounds of Formula (I), 2,4-disubstituted 4 H - thieno[3,2- c ]pyrrole-2-(substituted benzyl)pyridazin-3(2 H )-ones of Formula (II) and 6-(3,4-dimethylphenylaminosulfonyl)-3,4-dihydro-1 H -quinolin-2-one of formula (III), wherein L, R 1 , R 2 , R 11 to R 16 , R 21 and R 22 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia.
摘要:
The invention relates to a method for production of compounds of formula (I), starting from compounds of formula (II) and (III), the reaction medium containing at least one ionic liquid.
摘要:
Disclosed herein are compounds of formula I and methods used for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine- repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
摘要:
Compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
摘要:
The present invention provides an antiproliferative compound having the structural formula (I) wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.